2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2554

Inhibition of IL6 Receptor Improves Arthritis and Atherosclerosis in a Mouse Model of Rheumatoid Arthritis

Rheumatoid Arthritis - Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2974

Insulin Resistance Is Associated with the Digital Ulcer in Patients with Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2386

Integrating Wearable Physical Activity Monitoring Tools into Rehabilitation Practice for Patients with Arthritis: The Healthcare Professional Perspective

Orthopedics, Low Back Pain and Rehabilitation Poster (ARHP): Rehabilitation Sciences

9:00AM-11:00AM: Abstract Number: 2913

Intensified Treatment of B Lymphocyte Depletion (ITBLD) without Immunosuppressive Maintenance Treatment As a Rescue Therapy in Refractory Lupus Nephritis (LN): A 4-Year Observation

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2467

Interaction Between Senescent T Cells and Fibrocyte-like Cells through CD31, TNFα, and IL-17 Create a Tissue Destructive Environment in the Synovium in Juvenile Idiopathic Arthritis

Pediatric Rheumatology - Pathogenesis and Genetics Poster

9:00AM-11:00AM: Abstract Number: 2207

Interleukin-32Î³ Exhibited Protective Effects on Osteoporosis

Biology and Pathology of Bone and Joint: Bone Remodeling and Metabolism

9:00AM-11:00AM: Abstract Number: 2968

Interrater Reliability of Nailfold Capillaroscopy in Systemic Sclerosis Using Widefield Microscopy

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2375

Interstitial Lung Disease in Patients with Anti-PM-Scl Antibody

Muscle Biology, Myositis and Myopathies Poster II: Autoantibodies and Treatments in Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 2895

Intraarticular Sacroiliac Corticosteroid Injections in Ankylosing Spondylitis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2712

Intracellular O-Glc-Nac Alterations in Mononuclear Blood Cell of Rheumatoid Arthritis Patients

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 3000

Intrinsic Gene Expression Subset Predicts Improvement in Systemic Sclerosis Patients during Dasatinib (SprycelTM) Therapy

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 2296

Investigation of Environmental Associations of Fibromyalgia Pain Using Twitter Content Analysis

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II

9:00AM-11:00AM: Abstract Number: 2553

Involvement of M2 Macrophages in the Pathogenesis of Arthritis in a Mouse Model

Rheumatoid Arthritis - Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2862

Is Anti-TNF Tapering Possible in Patients with Axial Spondyloarthritis? a Systematic Literature Review

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2735

Is Disease Duration an Independent Predictor of Treatment Response Among Patients with Rheumatoid Arthritis Initiating Abatacept?

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].